B-Cell Hodgkin Lymphoma Pipeline market research report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects.
Key Targets in the B-Cell Hodgkin Lymphoma Pipeline Market
The key targets in the B-Cell Hodgkin Lymphoma Pipeline market are Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Histone Deacetylase 1, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, Histone Deacetylase, Histone Deacetylase 2, and Cells Expressing B Lymphocyte Antigen CD19. Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8 has the highest number of pipeline products.
B-Cell Hodgkin Lymphoma Pipeline Market, by Targets
For more target insights, download a free report sample
Types of MoA in the B-Cell Hodgkin Lymphoma Pipeline Market
The key mechanisms of action in the B-Cell Hodgkin Lymphoma Pipeline market are Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Histone Deacetylase 1 Inhibitor, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Histone Deacetylase 3 Inhibitor, Leukocyte Surface Antigen CD47 Inhibitor, and Hepatitis A Virus Cellular Receptor 2 Inhibitor. Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8 has the maximum number of pipeline products.
B-Cell Hodgkin Lymphoma Pipeline Market, by MoA
For more MoA insights, download a free report sample
Types of RoA in the B-Cell Hodgkin Lymphoma Pipeline Market
The types of key RoA in the B-Cell Hodgkin Lymphoma Pipeline market are intravenous, oral, parenteral, subcutaneous, intratumor, intravenous drip, intralesional, intraperitoneal, and topical. In the B-Cell Hodgkin Lymphoma Pipeline market, intravenous has the highest number of pipeline products.
B-Cell Hodgkin Lymphoma Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the B-Cell Hodgkin Lymphoma Pipeline Market
The key molecule types in the B-Cell Hodgkin Lymphoma Pipeline market are small molecule, monoclonal antibody, gene-modified cell therapy, monoclonal antibody conjugated, cell therapy, fusion protein, antibody, antisense RNAi oligonucleotide, gene therapy, and oligonucleotide. Small molecule has the highest number of pipeline products.
B-Cell Hodgkin Lymphoma Pipeline Market, by Molecule Type
For more molecule type insights, download a free report sample
Key Companies in the B-Cell Hodgkin Lymphoma Pipeline Market
The key companies in the B-Cell Hodgkin Lymphoma Pipeline market are Bristol-Myers Squibb Co, AstraZeneca Plc, Merck & Co Inc, Seagen Inc, Gilead Sciences Inc, Hebei Senlang Biotechnology Co Ltd, Incyte Corp, and Pfizer Inc. Bristol-Myers Squibb Co has the majority number of pipeline products.
B-Cell Hodgkin Lymphoma Pipeline Market, by Companies
To know more about companies, download a free report sample
Market report overview
| Key targets | Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Histone Deacetylase 1, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, Histone Deacetylase, Histone Deacetylase 2, and Cells Expressing B Lymphocyte Antigen CD19 |
| Key MoA | Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Histone Deacetylase 1 Inhibitor, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Histone Deacetylase 3 Inhibitor, Leukocyte Surface Antigen CD47 Inhibitor, and Hepatitis A Virus Cellular Receptor 2 Inhibitor |
| Key RoA | Intravenous, Oral, Parenteral, Subcutaneous, Intratumor, Intravenous Drip, Intralesional, Intraperitoneal, and Topical |
| Key molecule types | Small Molecule, Monoclonal Antibody, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, Cell Therapy, Fusion Protein, Antibody, Antisense RNAi Oligonucleotide, Gene Therapy, and Oligonucleotide |
| Key companies | Bristol-Myers Squibb Co, AstraZeneca Plc, Merck & Co Inc, Seagen Inc, Gilead Sciences Inc, Hebei Senlang Biotechnology Co Ltd, Incyte Corp, and Pfizer Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Stakeholders
Table of Contents
Tables
List of Tables
Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by AbbVie Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by ADC Therapeutics SA, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Adlai Nortye Biopharma Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Affimed GmbH, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Alfasigma SpA, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Angiocrine Bioscience Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Apollomics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Astellas Pharma Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by AstraZeneca Plc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Aurigene Discovery Technologies Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Avipep Pty Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bayer AG, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by BeiGene Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bio-Path Holdings Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bristol-Myers Squibb Co, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Carrick Therapeutics Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Catalent Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellectar Biosciences Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellectis SA, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celleron Therapeutics Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellestia Biotech AG, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellular Biomedicine Group Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celularity Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Checkmate Pharmaceuticals Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Checkpoint Therapeutics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Chimeric Therapeutics Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by CSL Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by CStone Pharmaceuticals Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Curis Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Daiichi Sankyo Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Dyadic International Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Eutilex Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Faron Pharmaceuticals Oy, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Genentech USA Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Gibson Oncology LLC, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Gilead Sciences Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Glenmark Pharmaceuticals Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Guangzhou Sinogen Pharmaceutical Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Hangzhou Sumgen Biotech Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Hebei Senlang Biotechnology Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Helocyte Biosciences Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by HRAIN Biotechnology Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Hutchison MediPharma Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Immune Cell Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Incyte Corp, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Inhibrx Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Innovent Biologics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Intellia Therapeutics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Kymera Therapeutics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by LegoChem Biosciences Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Luye Pharma Group Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Magenta Therapeutics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Marker Therapeutics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by MediSix Therapeutics Pte Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Merck & Co Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Merck KGaA, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Millennium Pharmaceuticals Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Miltenyi Biotec BV & Co KG, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Mirati Therapeutics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by NewBio Therapeutics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Northlake International LLC, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by OncoTartis Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Ono Pharmaceutical Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Pfizer Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by PlantForm Corp, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Protheragen Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rafael Pharmaceuticals Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by RAPT Therapeutics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Regeneron Pharmaceuticals Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rhizen Pharmaceuticals SA, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rich Pharmaceuticals Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Sanofi, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Seagen Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai First Song Therapeutics Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai YaKe Biotechnology Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shattuck Labs Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by SpecificiT Pharma Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Suzhou Everhealth Biomedical Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Syndax Pharmaceuticals Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tacitus Therapeutics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tessa Therapeutics Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tevogen Bio Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tubulis GmbH, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tyme Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Vincerx Pharma Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Viracta Therapeutics Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Waterstone Hanxbio Pty Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Xencor Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Discontinued Products, 2022
Graphs
List of Figures
Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022












